ASCO: AstraZeneca Achieves Eye-Catching Solid Tumor Results With 'Armored' CAR-T

Solid tumor CAR-T may succeed AZD7003 where many others have failed as the firm builds its cell therapy pipeline.

McCormick Place
The ASCO conference was once again held at McCormick Place in Chicago. • Source: Shutterstock

Numerous attempts to make CAR-Ts work in solid tumors have failed in recent years, but AstraZeneca has caught attention this week with promising Phase I data for its candidate, C-CAR031 (AZD7003), presented at the American Society of Oncology meeting in Chicago.

More from Clinical Trials

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Cassava At Crossroads As Simufilam Finally Exits, Stage Left

 

The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.

Sanofi Nabs Priority Review For MS Drug Tolebrutinib

 
• By 

A decision from the FDA is due by 28 September.

Novo Gets Its Own ‘Triple G’ Obesity Drug To Rival Lilly

 

The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.

More from R&D

Sanofi Nabs Priority Review For MS Drug Tolebrutinib

 
• By 

A decision from the FDA is due by 28 September.

Does Shingrix Really Lower Dementia Risk? GSK Funds Real World Research To Verify

 

A new “quasi-experimental” study using UK National Health Service data might confirm that GSK’s shingles vaccine helps cut dementia cases.

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By 

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process